A1319 the Responses of the Inflammatory Marker, Pentraxin 3, to Dietary Sodium and Potassium Interventions

Jiawen Hu,Jianjun Mu
DOI: https://doi.org/10.1097/01.hjh.0000548039.49779.1f
IF: 4.9
2018-01-01
Journal of Hypertension
Abstract:Objectives: Pentraxin-3 is a sensitive marker of inflammation that plays dual roles, pathogenic and cardioprotective, in the progression of cardiovascular diseases. Inflammation is intimately involved in salt-induced hypertension. We investigated the responses of pentraxin-3 to sodium and potassium supplementation to elucidate the potential role of pentraxin-3 in salt-induced hypertension. Methods: 48 participants were enrolled from northwest China. All subjects were maintained on a 3-day normal diet, which was sequentially followed by a 7-day low sodium diet, a 7-day high sodium diet and a 7-day high sodium plus potassium diet. Plasma concentrations of pentraxin-3 were assessed using ELISA. Results: Plasma pentraxin-3 decreased significantly during the low salt period compared to baseline (0.57 ± 0.19 ng/ml vs. 0.72 ± 0.33 ng/ml, p = 0.012) and increased during the high salt period (0.68 ± 0.26 ng/ml vs. 0.57 ± 0.19 ng/ml, p = 0.037). Potassium supplementation inhibited the salt-induced increase in pentraxin-3 (0.56 ± 0.21 ng/ml vs. 0.68 ± 0.26 ng/ml, p = 0.015). Ln-transformed pentraxin-3 at baseline was inversely correlated with BMI (r = −0.349, p = 0.02), DBP (r = −0.414, p = 0.005), MAP (r = −0.360, p = 0.017). We found a positive correlation between the ln-transformed concentrations of pentraxin-3 and 24-h urinary sodium during low and high Na+ periods (r = 0.269, p = 0.012) and a negative relationship with 24 h urinary potassium excretion during the high salt and high salt plus potassium period (r = − 0.246, p = 0.02). These correlations remained significant after adjusting for confounders. Pentraxin-3 responses were more prominent in salt sensitive subjects than salt- resistant subjects. Conclusion: Dietary salt and potassium interventions significantly altered circulating pentraxin-3.
What problem does this paper attempt to address?